Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | DDX3X | O00571 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592991 | 0.97 | KMT2A (0.68) | KMT2AMAPTPOLBMEN1DDX3X | |
| Hydrochloric Acid SCHEMBL1592637 | 0.95 | KMT2A (0.66) | KMT2AMAPTPOLBMEN1DDX3X | |
| SCHEMBL6725074 | 0.83 | KMT2A (0.72) | KMT2AMAPTPOLBMEN1DDX3X | |
| Nitric Acid SCHEMBL2075832 | 0.83 | KMT2A (0.53) | KMT2AMAPTPOLBMEN1DDX3X | |
| Nitric Acid SCHEMBL7231544 | 0.83 | KMT2A (0.53) | KMT2AMAPTPOLBMEN1DDX3X | |
| SCHEMBL14170 | 0.82 | KMT2A (0.75) | KMT2AMAPTPOLBMEN1DDX3X | |
| Nitric Acid SCHEMBL7234512 | 0.81 | MAPT (0.53) | KMT2AMAPTMEN1HTTALDH1A1 | |
| Nitric Acid SCHEMBL1363668 | 0.81 | MEN1 (0.50) | KMT2AMAPTPOLBMEN1HTT | |
| Nitric Acid SCHEMBL1880262 | 0.81 | CYP1A2 (0.54) | KMT2AMAPTMEN1HTTSMN1; SMN2 | |
| Nitric Acid SCHEMBL3250036 | 0.81 | MEN1 (0.48) | KMT2AMAPTMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102372690-B | Intermediate for synthesizing imatinib and application of intermediate in imatinib synthesis | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD | 2014-05-28 | — | — | CN | disclosed |
| CN-101654416-B | N-[3-nitro-4-methyl-phenyl]-4-aldehyde group-benzamide and preparation method thereof as well as preparation method of derivatives thereof | CHENGDU SHENHUANG MEDICINE TECHNOLOGY CO LTD | 2013-06-05 | — | — | CN | disclosed |
| CN-102372690-A | Intermediate for synthesizing imatinib and application of intermediate in imatinib synthesis | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD | 2012-03-14 | — | — | CN | disclosed |
| US-20110195968-A1 | THIAZOLES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-08-11 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| CN-101654416-A | N-[3-nitro-4-methyl-phenyl]-4-aldehyde group-benzamide and preparation method thereof as well as preparation method of derivatives thereof | CHENGDU HUTCHISON CHINA MEDICI | 2010-02-24 | — | — | CN | disclosed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-7595323-B2 | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | IL YANG PHARM. CO., LTD. (KR) | 2009-09-29 | — | — | US | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | disclosed |
| CN-1043531-C | Pyrimidine derivatives and a process for production thereof | NOVATIS AG (CH) | 1999-06-02 | — | — | CN | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| CN-1077713-A | Pyrimidine derivatives and preparation method thereof | CIBA GEIGY AG (CH) | 1993-10-27 | — | — | CN | disclosed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | disclosed |
| US-4724200-A | CRYSTAL STRUCTURE | EASTMAN KODAK COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | KMT2A 526/4885MAPT 2289/4885POLB 180/4885 |
| US-20110195968-A1 | THIAZOLES AS FUNGICIDES | CYP4X1, CYP4Z1, CYP3A4 | KMT2A 3186/4885MAPT 2586/4885POLB 4560/4885 |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | KMT2A 1495/4885MAPT 1185/4885POLB 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.